Sort By
-
Justine Bruce
New therapeutics are urgently needed for hormone..
Justine Bruce
The 2010 PCF Young Investigator in Honor of Our Soldiers and the Department of Defense Congressionally Directed Medical Research Program for Prostate Cancer
Justine Bruce, MD:
University of Wisconsin Carbone Comprehensive Cancer Center – Madison, WI
Mentor:
Glenn Liu, MD, Associate Professor of Medicine, Section of Medical Oncology and Hematology, at the University of Wisconsin Carbone Comprehensive Cancer Center.
-
Himisha Beltran
Dr. Beltran’s research will help define the..
Himisha Beltran
The 2010 LeFrak Family – PCF Young Investigator Award
Himisha Beltran, MD:
Weill Cornell Medical College – New York, NY
Co-Mentor:
David Nanus, MD, Medical Director of the Genitourinary Oncology Program and Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medical College.
Co-Mentor:
Mark Rubin, MD, Professor of Pathology and Laboratory Medicine, Director of Translational Research Laboratory Services, and Vice Chairman for Experimental Pathology at Weill Cornell Medical College.
-
John Chadwick Brenner
More than 50% of prostate cancers have..
John Chadwick Brenner
The 2011 Albert Fuss – PCF Young Investigator Award
(first year)Award1:
The 2011 Cayre Family Foundation – PCF Young Investigator Award (second year)
(first year)Award2:
The 2011 Robert Kraft – PCF Young Investigator Award (third year)
John Chadwick Brenner, MSc, PhD:
University of Michigan
Mentor:
Arul Chinnaiyan, MD, PhD
-
Tarek Bismar
Dr. Bismar earned an MD degree from..
Tarek Bismar
The 2008 Robbins Family – PCF Young Investigator Award
The 2012 Robbins Family – PCF Young Investigator AwardTarek Bismar, MD:
University of Calgary – Canada
-
W. Nathaniel Brennen
T cells are a type of immune..
W. Nathaniel Brennen
2014 Clay and Lynn Hamlin-PCF Young Investigator
W. Nathaniel Brennen, PhD:
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mentors:
John Isaacs, PhD, Charles Drake, MD, PhD
Proposal Title:
T cells Engineered to Selectively Deliver a PSA-activated Protoxin to Sites of Advanced Prostate Cancer
-
Jennifer Bishop
Approximately 25% of patients who fail Xtandi..
Jennifer Bishop
2013 Millennium Pharma-PCF Young Investigator
Jennifer Bishop, PhD:
University of British Columbia
Mentors:
Martin Gleave, MD and Amina Zoubeidi, PhD
Project Title:
Regulation of cell plasticity by the androgen receptor: A novel mechanism of enzalutamide (Xtandi) resistance
-
Kelvin A. Baggett, MD, MPH, MBA
A nationally recognized, strategic, results-oriented leader with..
Kelvin A. Baggett, MD, MPH, MBA
Managing Director, Head of Patient Impact and Chair
EMPIRIC Institute
